JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation
We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for S...
Saved in:
Published in | BMC immunology Vol. 18; no. 1; p. 41 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
BioMed Central Ltd
22.08.2017
BioMed Central |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE.
We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4
T cells (SLE mice) and CD3
T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naïve CD4
T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4
from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3
T cells from human patients following immunosuppressant therapy including steroid, respectively.
Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. |
---|---|
AbstractList | We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE. We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4.sup.+ T cells (SLE mice) and CD3.sup.+ T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naïve CD4.sup.+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4.sup.+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3.sup.+ T cells from human patients following immunosuppressant therapy including steroid, respectively. Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. Background We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE. Results We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4+ T cells (SLE mice) and CD3+ T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naive CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively. Conclusion Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. BACKGROUNDWe previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE.RESULTSWe treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4+ T cells (SLE mice) and CD3+ T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naïve CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively.CONCLUSIONModulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. Background We previously reported that JAK–STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK–STAT pathway and as a therapeutic for SLE. Results We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4+ T cells (SLE mice) and CD3+ T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naïve CD4+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3+ T cells from human patients following immunosuppressant therapy including steroid, respectively. Conclusion Modulation of type I IFN signalling via JAK–STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE. We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4 T cells (SLE mice) and CD3 T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naïve CD4 T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4 from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3 T cells from human patients following immunosuppressant therapy including steroid, respectively. Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. Background We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we evaluated the efficacy of the JAK inhibitor tofacitinib (TOFA) for controlling IFN signalling via the JAK-STAT pathway and as a therapeutic for SLE. Results We treated NZB/NZW F1 mice with TOFA and assessed alterations in their disease, pathological, and immunological conditions. Gene-expression results obtained from CD4.sup.+ T cells (SLE mice) and CD3.sup.+ T cells (human SLE patients) were measured by DNA microarray and qRT-PCR. TOFA treatment resulted in reduced levels of anti-dsDNA antibodies, decreased proteinuria, and amelioration of nephritis as compared with those observed in control animals. Moreover, we observed the rebalance in the populations of naïve CD4.sup.+ T cells and effector/memory cells in TOFA-treated mice; however, treatment with a combination of TOFA and dexamethasone (DEXA) elicited a stronger inhibitory effect toward the effector/memory cells than did TOFA or DEXA monotherapy. We also detected decreased expression of several IFN-signature genes Ifit3 and Isg15 in CD4.sup.+ from SLE-prone mice following TOFA and DEXA treatment, and IFIT3 in CD3.sup.+ T cells from human patients following immunosuppressant therapy including steroid, respectively. Conclusion Modulation of type I IFN signalling via JAK-STAT inhibition may exert a beneficial effect in SLE patients, and our results suggest that TOFA could be utilised for the development of new SLE-specific therapeutic strategies. Keywords: Systemic lupus erythematosus, Interferon, Cytokines, T cells, JAK-STAT pathway, Translational research |
ArticleNumber | 41 |
Audience | Academic |
Author | Ikeda, Keigo Sekigawa, Iwao Hayakawa, Kunihiro Hirai, Takuya Takamori, Kenji Ogawa, Hideoki Miyashita, Tomoko Kawasaki, Mikiko Morimoto, Shinji Tamura, Naoto Tsushima, Hiroshi Fujishiro, Maki Suzuki, Satoshi |
Author_xml | – sequence: 1 givenname: Keigo orcidid: 0000-0002-8032-7147 surname: Ikeda fullname: Ikeda, Keigo email: keigo@juntendo.ac.jp, keigo@juntendo.ac.jp organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan. keigo@juntendo.ac.jp – sequence: 2 givenname: Kunihiro surname: Hayakawa fullname: Hayakawa, Kunihiro organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 3 givenname: Maki surname: Fujishiro fullname: Fujishiro, Maki organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 4 givenname: Mikiko surname: Kawasaki fullname: Kawasaki, Mikiko organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 5 givenname: Takuya surname: Hirai fullname: Hirai, Takuya organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 6 givenname: Hiroshi surname: Tsushima fullname: Tsushima, Hiroshi organization: Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan – sequence: 7 givenname: Tomoko surname: Miyashita fullname: Miyashita, Tomoko organization: Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan – sequence: 8 givenname: Satoshi surname: Suzuki fullname: Suzuki, Satoshi organization: Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, 2-1-1 Tomioka Urayasu-shi, Chiba, 279-0021, Japan – sequence: 9 givenname: Shinji surname: Morimoto fullname: Morimoto, Shinji organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 10 givenname: Naoto surname: Tamura fullname: Tamura, Naoto organization: Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan – sequence: 11 givenname: Kenji surname: Takamori fullname: Takamori, Kenji organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 12 givenname: Hideoki surname: Ogawa fullname: Ogawa, Hideoki organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan – sequence: 13 givenname: Iwao surname: Sekigawa fullname: Sekigawa, Iwao organization: Institutes for Environmental and Gender Specific Medicine, Juntendo University Graduate School of Medicine, Chiba, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28830352$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kk1v1DAQhiNURD_gB3BBlrjAIcUfceJwQFpVFBYqkPg4W44zzrpK7MV2Fvj3eHdL6SKE5mDLfub1jOc9LY6cd1AUjwk-J0TULyKhouYlJk2JKeVle684IVVDSkoaenRnf1ycxniNMyioeFAcUyEYZpyeFPHd4j2ybmU7m3xAKxVRWgFSE4zWB5WsdwiMAZ0yhcZ5PcdyHXIZaLIaXu5g6zZ-3MAELiFv0PLyA4p2cCrNAdAAme39dxdgmMed4MPivlFjhEc361nx9fL1l4u35dXHN8uLxVWpa0pT2XUUBKaAK9Ib3FGNGYPcQa1bzTgWVduwThgsCCdKGegNF41mSmtGVNsYdla82uuu526CXuf6ghrlOthJhZ_SKysPb5xdycFvJOe1wFWTBZ7dCAT_bYaY5GSjhnFUDvwcJWkZaUgtdujTv9BrPweX25OUc4HrbfyPylpVjSvK-B9qUCNI64zP1ent03LBCaEN4S3N1Pk_qBw95NHkCRmbzw8Snh8kZCbBjzSoOUa5_PzpkCV7VgcfYwBz-2sEy6335N57MltKbr0n25zz5O5332b8Nhv7BQ711Iw |
CitedBy_id | crossref_primary_10_3389_fimmu_2021_653989 crossref_primary_10_1080_1744666X_2022_2040988 crossref_primary_10_1080_13543784_2019_1551358 crossref_primary_10_1007_s10067_022_06400_y crossref_primary_10_1016_j_bbrc_2020_06_157 crossref_primary_10_1016_j_intimp_2020_106480 crossref_primary_10_1111_jcmm_16407 crossref_primary_10_1007_s12016_020_08786_6 crossref_primary_10_1016_j_autrev_2019_102390 crossref_primary_10_1080_17460441_2018_1480718 crossref_primary_10_2147_JIR_S397639 crossref_primary_10_1097_BOR_0000000000000524 crossref_primary_10_29235_1561_8323_2023_67_3_222_230 crossref_primary_10_3389_fimmu_2019_00975 crossref_primary_10_1093_cei_uxac012 crossref_primary_10_1016_j_jaut_2022_102990 crossref_primary_10_1016_j_bcp_2021_114760 crossref_primary_10_1093_cei_uxac096 crossref_primary_10_3389_fimmu_2023_1288675 crossref_primary_10_1016_j_cyto_2022_155877 crossref_primary_10_2174_0929867325666180209145243 crossref_primary_10_1111_1346_8138_16741 crossref_primary_10_1080_1744666X_2022_2047022 crossref_primary_10_3389_fimmu_2021_654376 crossref_primary_10_3928_19382359_20220118_01 crossref_primary_10_1016_j_rdc_2021_04_001 crossref_primary_10_1016_j_jphs_2021_02_002 crossref_primary_10_14412_1995_4484_2019_452_461 crossref_primary_10_14412_1995_4484_2020_214_224 crossref_primary_10_14412_1995_4484_2019_8_16 crossref_primary_10_3389_fmed_2023_1217147 crossref_primary_10_1007_s40265_023_01856_x crossref_primary_10_1146_annurev_pathol_020117_043952 crossref_primary_10_3390_ijms231911788 crossref_primary_10_3390_cells8080898 crossref_primary_10_1016_j_jaut_2020_102424 crossref_primary_10_1002_cti2_1362 crossref_primary_10_3389_fimmu_2023_1271102 crossref_primary_10_14789_jmj_2018_64_JMJ18_R03 crossref_primary_10_1186_s13075_021_02470_6 crossref_primary_10_3389_fmed_2020_607725 crossref_primary_10_1093_mr_road024 crossref_primary_10_1007_s40674_020_00155_w crossref_primary_10_1016_j_clim_2018_08_013 crossref_primary_10_1097_BOR_0000000000000474 crossref_primary_10_3389_fimmu_2022_1034880 crossref_primary_10_46497_ArchRheumatol_2022_8252 crossref_primary_10_3389_fimmu_2021_675542 |
Cites_doi | 10.1007/s10238-006-0103-x 10.1517/14740338.2015.986455 10.1191/0961203304lu1012ed 10.1177/0961203311409963 10.1073/pnas.93.1.211 10.1007/s10875-015-0203-z 10.1073/pnas.0900615106 10.1097/01.ASN.0000108969.21691.5D 10.1016/j.molmed.2004.09.007 10.1155/2012/347141 10.1016/j.immuni.2012.03.014 10.1016/j.jaut.2013.04.003 10.1371/journal.pone.0051118 10.4049/jimmunol.1600624 10.1038/sj.gene.6364408 10.1136/lupus-2014-000080 10.1002/art.24567 10.1016/j.jaut.2016.06.020 10.1371/journal.pone.0083776 10.1002/jcb.21535 10.1093/rheumatology/kev346 10.1002/acr.21664 10.1016/j.jaut.2015.05.007 10.1155/2014/283617 10.1084/jem.130.2.203 10.1016/j.clim.2017.04.015 10.1177/0961203308089694 10.1136/annrheumdis-2015-207319 10.1126/science.1079490 10.1177/0961203307088307 10.1136/annrheumdis-2014-206090 10.2353/ajpath.2008.080314 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2017 BioMed Central Ltd. Copyright BioMed Central 2017 2017. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2017 |
Copyright_xml | – notice: COPYRIGHT 2017 BioMed Central Ltd. – notice: Copyright BioMed Central 2017 – notice: 2017. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2017 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION ISR 3V. 7T5 7X7 7XB 88E 8C1 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M1P M7P PIMPY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
DOI | 10.1186/s12865-017-0225-9 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Science in Context ProQuest Central (Corporate) Immunology Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Public Health Database ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences Health & Medical Collection (Alumni Edition) Medical Database Biological Science Database Publicly Available Content Database ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Publicly Available Content Database ProQuest Central Student ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest Central (Alumni) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic Publicly Available Content Database MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1471-2172 |
EndPage | 41 |
ExternalDocumentID | A511271592 10_1186_s12865_017_0225_9 28830352 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Japan |
GeographicLocations_xml | – name: Japan |
GrantInformation_xml | – fundername: ; grantid: S1311011 – fundername: ; grantid: JP15K08107 |
GroupedDBID | --- -A0 0R~ 23N 2WC 3V. 53G 5VS 6J9 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ ABDBF ABUWG ACGFO ACGFS ACIHN ACMJI ACPRK ACRMQ ADBBV ADINQ ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BHPHI BMC BPHCQ C24 C6C CCPQU CGR CS3 CUY CVF DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS ECM EIF EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 H13 HCIFZ HMCUK HYE IAO IHR INH INR ISR ITC KQ8 M1P M48 M7P M~E NPM O5R O5S OK1 P2P PGMZT PIMPY PROAC PSQYO RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX CITATION AFGXO 7T5 7XB 8FE 8FH 8FK AHSBF AZQEC BVXVI DWQXO GNUQQ H94 K9. LK8 PQEST PQQKQ PQUKI PRINS 7X8 5PM |
ID | FETCH-LOGICAL-c622t-bb2e802e041df0b2c033e1786c9c35084973b8f08151aafedf587c3acc31a97f3 |
IEDL.DBID | RPM |
ISSN | 1471-2172 |
IngestDate | Tue Sep 17 21:22:22 EDT 2024 Fri Oct 25 23:31:36 EDT 2024 Thu Oct 10 15:51:36 EDT 2024 Thu Oct 10 16:23:13 EDT 2024 Tue Nov 19 21:24:49 EST 2024 Tue Nov 12 22:09:49 EST 2024 Thu Aug 01 20:14:24 EDT 2024 Thu Sep 12 16:27:10 EDT 2024 Wed Oct 16 00:57:01 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Translational research Interferon Systemic lupus erythematosus Cytokines T cells JAK–STAT pathway |
Language | English |
License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c622t-bb2e802e041df0b2c033e1786c9c35084973b8f08151aafedf587c3acc31a97f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0002-8032-7147 |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568047/ |
PMID | 28830352 |
PQID | 1934604235 |
PQPubID | 44823 |
PageCount | 1 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5568047 proquest_miscellaneous_1931716847 proquest_journals_2558060606 proquest_journals_1934604235 gale_infotracmisc_A511271592 gale_infotracacademiconefile_A511271592 gale_incontextgauss_ISR_A511271592 crossref_primary_10_1186_s12865_017_0225_9 pubmed_primary_28830352 |
PublicationCentury | 2000 |
PublicationDate | 2017-08-22 |
PublicationDateYYYYMMDD | 2017-08-22 |
PublicationDate_xml | – month: 08 year: 2017 text: 2017-08-22 day: 22 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England – name: London |
PublicationTitle | BMC immunology |
PublicationTitleAlternate | BMC Immunol |
PublicationYear | 2017 |
Publisher | BioMed Central Ltd BioMed Central |
Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central |
References | 4183483 - J Exp Med. 1969 Aug 1;130(2):203-16 18413409 - Lupus. 2008 Apr;17(4):289-94 23226562 - PLoS One. 2012;7(12):e51118 28461107 - Clin Immunol. 2017 Apr 28;:null 17061057 - Clin Exp Med. 2006 Oct;6(3):99-106 8552607 - Proc Natl Acad Sci U S A. 1996 Jan 9;93(1):211-5 26453583 - J Clin Immunol. 2015 Oct;35(7):661-7 19279210 - Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5294-9 24883332 - J Immunol Res. 2014;2014:283617 22520847 - Immunity. 2012 Apr 20;36(4):542-50 26318385 - Ann Rheum Dis. 2016 Jun;75(6):1133-8 19008373 - Am J Pathol. 2008 Dec;173(6):1682-92 22556106 - Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808 18755862 - Lupus. 2008 Sep;17(9):805-13 26094774 - J Autoimmun. 2015 Aug;62:11-21 26038091 - Ann Rheum Dis. 2016 Jan;75(1):196-202 27357150 - J Immunol. 2016 Aug 15;197(4):1447-59 14747370 - J Am Soc Nephrol. 2004 Feb;15(2):241-50 15176655 - Lupus. 2004;13(4):217-22 23623029 - J Autoimmun. 2013 Jun;43:78-84 22500087 - J Biomed Biotechnol. 2012;2012:347141 26424838 - Rheumatology (Oxford). 2016 May;55(5):775-9 17910035 - J Cell Biochem. 2007 Dec 1;102(5):1087-94 15519279 - Trends Mol Med. 2004 Nov;10 (11):532-41 19565475 - Arthritis Rheum. 2009 Jul;60(7):1895-905 21980035 - Lupus. 2011 Oct;20(12):1231-9 19473566 - Clin Exp Rheumatol. 2009 Mar-Apr;27(2):260-6 25483011 - Expert Opin Drug Saf. 2015 Feb;14(2):243-51 25861459 - Lupus Sci Med. 2015 Mar 28;2(1):e000080 17581626 - Genes Immun. 2007 Sep;8(6):492-502 12522256 - Science. 2003 Feb 14;299(5609):1057-61 24391825 - PLoS One. 2013 Dec 31;8(12):e83776 27396525 - J Autoimmun. 2016 Nov;74:118-138 P Coit (225_CR29) 2013; 43 DL Su (225_CR5) 2012; 2012 H Long (225_CR18) 2016; 74 225_CR22 DC Borie (225_CR9) 2004; 10 C Kyogoku (225_CR31) 2013; 8 I Sekigawa (225_CR1) 2006; 6 JJ Weening (225_CR16) 2004; 15 D Zagury (225_CR25) 2009; 106 JJ O'Shea (225_CR7) 2012; 36 J Abe (225_CR24) 2008; 173 BC Seegal (225_CR15) 1969; 130 S Yokoyama (225_CR20) 2015; 35 KC Kalunian (225_CR28) 2016; 75 J D'Cunha (225_CR32) 1996; 93 MI Vargas-Rojas (225_CR23) 2008; 17 BH Hahn (225_CR21) 2012; 64 N Shaabani (225_CR26) 2015; 62 JM Kremer (225_CR10) 2009; 60 L Vila (225_CR17) 2012; 7 MA Care (225_CR33) 2016; 197 L Hsu (225_CR12) 2014; 2014 225_CR14 I Sekigawa (225_CR3) 2004; 13 225_CR11 M Aringer (225_CR13) 2015; 14 J Tang (225_CR30) 2008; 17 WP Kennedy (225_CR27) 2015; 2 M Kawasaki (225_CR8) 2011; 20 M Kawasaki (225_CR2) 2009; 27 Z Du (225_CR6) 2007; 102 TB Niewold (225_CR4) 2007; 8 S Hori (225_CR19) 2003; 299 |
References_xml | – volume: 6 start-page: 99 issue: 3 year: 2006 ident: 225_CR1 publication-title: Clin Exp Med doi: 10.1007/s10238-006-0103-x contributor: fullname: I Sekigawa – volume: 14 start-page: 243 issue: 2 year: 2015 ident: 225_CR13 publication-title: Expert Opin Drug Saf doi: 10.1517/14740338.2015.986455 contributor: fullname: M Aringer – volume: 13 start-page: 217 issue: 4 year: 2004 ident: 225_CR3 publication-title: Lupus doi: 10.1191/0961203304lu1012ed contributor: fullname: I Sekigawa – volume: 20 start-page: 1231 issue: 12 year: 2011 ident: 225_CR8 publication-title: Lupus doi: 10.1177/0961203311409963 contributor: fullname: M Kawasaki – volume: 93 start-page: 211 issue: 1 year: 1996 ident: 225_CR32 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.93.1.211 contributor: fullname: J D'Cunha – volume: 35 start-page: 661 issue: 7 year: 2015 ident: 225_CR20 publication-title: J Clin Immunol doi: 10.1007/s10875-015-0203-z contributor: fullname: S Yokoyama – volume: 106 start-page: 5294 issue: 13 year: 2009 ident: 225_CR25 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0900615106 contributor: fullname: D Zagury – volume: 15 start-page: 241 issue: 2 year: 2004 ident: 225_CR16 publication-title: J Am Soc Nephrol doi: 10.1097/01.ASN.0000108969.21691.5D contributor: fullname: JJ Weening – volume: 10 start-page: 532 issue: 11 year: 2004 ident: 225_CR9 publication-title: Trends Mol Med doi: 10.1016/j.molmed.2004.09.007 contributor: fullname: DC Borie – volume: 2012 start-page: 347141 year: 2012 ident: 225_CR5 publication-title: J Biomed Biotechnol doi: 10.1155/2012/347141 contributor: fullname: DL Su – volume: 36 start-page: 542 issue: 4 year: 2012 ident: 225_CR7 publication-title: Immunity doi: 10.1016/j.immuni.2012.03.014 contributor: fullname: JJ O'Shea – volume: 27 start-page: 260 issue: 2 year: 2009 ident: 225_CR2 publication-title: Clin Exp Rheumatol contributor: fullname: M Kawasaki – volume: 43 start-page: 78 year: 2013 ident: 225_CR29 publication-title: J Autoimmun doi: 10.1016/j.jaut.2013.04.003 contributor: fullname: P Coit – volume: 7 start-page: e51118 issue: 12 year: 2012 ident: 225_CR17 publication-title: PLoS One doi: 10.1371/journal.pone.0051118 contributor: fullname: L Vila – volume: 197 start-page: 1447 issue: 4 year: 2016 ident: 225_CR33 publication-title: J Immunol doi: 10.4049/jimmunol.1600624 contributor: fullname: MA Care – volume: 8 start-page: 492 issue: 6 year: 2007 ident: 225_CR4 publication-title: Genes Immun doi: 10.1038/sj.gene.6364408 contributor: fullname: TB Niewold – volume: 2 issue: 1 year: 2015 ident: 225_CR27 publication-title: Lupus Sci Med doi: 10.1136/lupus-2014-000080 contributor: fullname: WP Kennedy – volume: 60 start-page: 1895 issue: 7 year: 2009 ident: 225_CR10 publication-title: Arthritis Rheum doi: 10.1002/art.24567 contributor: fullname: JM Kremer – volume: 74 start-page: 118 year: 2016 ident: 225_CR18 publication-title: J Autoimmun doi: 10.1016/j.jaut.2016.06.020 contributor: fullname: H Long – volume: 8 issue: 12 year: 2013 ident: 225_CR31 publication-title: PLoS One doi: 10.1371/journal.pone.0083776 contributor: fullname: C Kyogoku – volume: 102 start-page: 1087 issue: 5 year: 2007 ident: 225_CR6 publication-title: J Cell Biochem doi: 10.1002/jcb.21535 contributor: fullname: Z Du – ident: 225_CR14 doi: 10.1093/rheumatology/kev346 – volume: 64 start-page: 797 issue: 6 year: 2012 ident: 225_CR21 publication-title: Arthritis Care Res (Hoboken) doi: 10.1002/acr.21664 contributor: fullname: BH Hahn – volume: 62 start-page: 11 year: 2015 ident: 225_CR26 publication-title: J Autoimmun doi: 10.1016/j.jaut.2015.05.007 contributor: fullname: N Shaabani – volume: 2014 start-page: 283617 year: 2014 ident: 225_CR12 publication-title: J Immunol Res doi: 10.1155/2014/283617 contributor: fullname: L Hsu – volume: 130 start-page: 203 issue: 2 year: 1969 ident: 225_CR15 publication-title: J Exp Med doi: 10.1084/jem.130.2.203 contributor: fullname: BC Seegal – ident: 225_CR22 doi: 10.1016/j.clim.2017.04.015 – volume: 17 start-page: 805 issue: 9 year: 2008 ident: 225_CR30 publication-title: Lupus doi: 10.1177/0961203308089694 contributor: fullname: J Tang – ident: 225_CR11 doi: 10.1136/annrheumdis-2015-207319 – volume: 299 start-page: 1057 issue: 5609 year: 2003 ident: 225_CR19 publication-title: Science doi: 10.1126/science.1079490 contributor: fullname: S Hori – volume: 17 start-page: 289 issue: 4 year: 2008 ident: 225_CR23 publication-title: Lupus doi: 10.1177/0961203307088307 contributor: fullname: MI Vargas-Rojas – volume: 75 start-page: 196 issue: 1 year: 2016 ident: 225_CR28 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2014-206090 contributor: fullname: KC Kalunian – volume: 173 start-page: 1682 issue: 6 year: 2008 ident: 225_CR24 publication-title: Am J Pathol doi: 10.2353/ajpath.2008.080314 contributor: fullname: J Abe |
SSID | ssj0017828 |
Score | 2.3983364 |
Snippet | We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis. Here, we... Background We previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis.... Background We previously reported that JAK–STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis.... BACKGROUNDWe previously reported that JAK-STAT-pathway mediated regulation of IFN-regulatory factor genes could play an important role in SLE pathogenesis.... |
SourceID | pubmedcentral proquest gale crossref pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
StartPage | 41 |
SubjectTerms | Adult Aged Animals Anti-DNA antibodies Anti-Inflammatory Agents - pharmacology Anti-Inflammatory Agents - therapeutic use Antibodies Arthritis CD3 antigen CD4 antigen CD4-Positive T-Lymphocytes - drug effects CD4-Positive T-Lymphocytes - metabolism Cellular signal transduction Comparative analysis Cytokines Cytokines - genetics Cytokines - metabolism Development and progression Dexamethasone Dexamethasone - pharmacology Dexamethasone - therapeutic use DNA methylation DNA microarrays Down-Regulation - drug effects Down-Regulation - immunology Dual energy X-ray absorptiometry Effector cells Female Furans - pharmacology Furans - therapeutic use Gene expression Gene regulation Genes Genetic aspects Health aspects Humans Immunological memory Interferon Intracellular Signaling Peptides and Proteins - genetics Intracellular Signaling Peptides and Proteins - metabolism Janus Kinase Inhibitors - pharmacology Janus Kinase Inhibitors - therapeutic use Kidneys Kinases Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - genetics Lupus Erythematosus, Systemic - immunology Lymphocytes Lymphocytes T Memory cells Mice Mice, Inbred MRL lpr Mice, Inbred NZB Middle Aged Nephritis Pathogenesis Patients Physiological aspects Proteins - genetics Proteins - metabolism Proteinuria Rodents Signal transduction Signal Transduction - drug effects Spleen Systemic lupus erythematosus T-Lymphocyte Subsets - drug effects T-Lymphocyte Subsets - immunology Young Adult |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Ri9QwEB50D8UX0VPP6ilRBEEI16Zpm_oiq9xyd3KLnB7cW2jS1C2c3XW7ffDfO9Nm16uI7GOGkM1MZr50Jt8AvEmNsi6SJc-FslyaMOFFLmPuXFJSTDK2z56fz9OTS3l2lVz5D26tL6vc-sTeUZdLS9_IjxBoyJSKOJIPq5-cukZRdtW30LgNeyKKlZrA3sfj-ZeLXR4B45_yucxIpUdtRA8xOXlmjF0Jz0fR6G-ffCMojQsmb0Sg2QO476Ejmw66fgi3XLMPd4Zmkr_24e65T5M_gvZs-pnVzaI2eF7XbFG0DHEeK36469qrnA2FHCjFrrtV13JcTuMYNad_3wvXDTqunkx8w5YVO53NGdV69DygDK3OsRIv8OuhlT1O-BguZ8ffPp1w312B21SIDTdGOBUKF8qorEIjbBjHDjcstbmNEbbJPIuNqhAyJFFRVK6sEpXZuLA2joo8q-InMGlwZU-BVVLiRlcExhAQpMrEIiktIglHD2-VCuDddpf1aiDR0P3lQ6V6UIlGlWhSic4DeE160ERO0VD1y_eia1t9-vVCTwkdZgjARABvvVC1RI3Ywj8mwPUQn9VI8nAkiafHjoe36tb-9Lb6j639cxhvYSpM6RfAq90wTUwFa41bdv0URESEsT-Ag8F4dn-dGjwTDW0A2cisdgJE-T0eaepFT_1NfHGhzJ79f9XP4Z7obRydoDiEyWbduReInTbmpT8gvwH7hhgk priority: 102 providerName: ProQuest – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3di9QwEB_OE8UX0fOrekoUQRDitWnapoLIIi53J3sP6sK9hSZN3YW97t12C95_70zaXa-yL9LHDCHNfP1CJr8BeJsaZV0kS54LZbk0YcKLXMbcuaSknGSsvz2fnKXHU3l6npzvwaa9Vb-Bzc6jHfWTmq4WH35fXX9Gh__kHV6lR01Ezys5xVvMSAnPb8FtgYmRKrwm8u-lAiZD_zIO4zGnvkz9JefOKQZp6t9gfSNbDSspb6Sm8QO432NKNuqM4CHsufoA7nRdJq8P4O6kvz9_BM3p6Bub17O5QUdesVnRMASArLhwi3lvC6yr8EAptmgv24bjcmrHqGv9Ry88rzGieZbxNVtW7GR8xqgIxBOEMjRHx0o82a-6Hvc44WOYjr_-_HLM-7YL3KZCrLkxwqlQuFBGZRUaYcM4drh5qc1tjHhO5llsVIVYIomKonJllajMxoW1cVTkWRU_gf0aV_YMWCUlbnpFKA2RQqpMLJLSIsRw9CJXqQDeb3ZZX3bsGtqfSlSqO5VoVIkmleg8gDekB02sFTWVxfwq2qbRJz--6xHBxgyRmQjgXS9ULVEjtuhfGeB6iOhqIHk4kES3ssPhjbr1xio1ol2ZUiVRsnMYj2cqTOkL4PV2mCamSrbaLVs_BTEUISgI4GlnPNtfp87PxE8bQDYwq60AcYEPR-r5zHOCE5FcKLPn_7OhL-Ce8BaPsVIcwv561bqXCLHW5pV3nD_GGR84 priority: 102 providerName: Scholars Portal |
Title | JAK inhibitor has the amelioration effect in lupus-prone mice: the involvement of IFN signature gene downregulation |
URI | https://www.ncbi.nlm.nih.gov/pubmed/28830352 https://www.proquest.com/docview/1934604235 https://www.proquest.com/docview/2558060606 https://search.proquest.com/docview/1931716847 https://pubmed.ncbi.nlm.nih.gov/PMC5568047 |
Volume | 18 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fb9MwED5tQyBeEAwYgVEZhISElDU_nMThrVSrtqFW02DS3qzYcWikNq2a9oH_njsnqRrEE4qUF18s1-fzfa7vvgP4FCuhjc9zNw2EdrnyIjdLeegaE-Xkk5S2t-fTWXx1z28eoocjiLpcGBu0r1V5US2WF1U5t7GV66UednFiw9vpmFizPJ4Mj-EY3W93RG-vDtDlifb60hfxsPYp99KlzRjdVeQSTShV2PVsrtGBL_p7Rz5wSf1wyQP_M3kOz1rgyEbNAF_AkalO4XFTSvL3KTyZtpfkL6G-GX1nZTUvFVrrhs2zmiHKY9nSLMpW4awJ40Apttitd7WLw6kMo9L0X61wWeG2ZanEt2xVsOvJjFGkh2UBZbjmDMvx-L5pCtljh6_gfnL5c3zltrUVXB0HwdZVKjDCC4zH_bzwVKC9MDQ4d7FOdYigjadJqESBgCHys6wweRGJRIeZ1qGfpUkRvoaTCkf2BljBOc55QVAM4UAsVBhEuUYcYSjtVggHvnSzLNcNhYa0Rw8Ry0Y7ErUjSTsydeAj6UESNUVFsS-_sl1dy-sfd3JE2DBB-BU48LkVKlaoEZ21qQQ4HmKz6kme9yTRdnS_uVO3bG23lghpeUzhQtE_m_EMJryYHgc-7JupYwpXq8xqZ7sgGiL0_A6cNYtn_9O7xedA0ltWewEi_O63oB1Y4u923b_97y_fwdPAWgLujsE5nGw3O_MeQdVWDdCUHhJ8i7E_gEffLme3dwP7BwW-p1wMrJH9AWwhJOA |
link.rule.ids | 230,314,727,780,784,864,885,12056,12223,21388,24318,27924,27925,31719,31720,33266,33267,33744,33745,43310,43579,43805,53791,53793 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwED9BJz5eEAwGgQEGISEhWUucL4cXVNCqdlsrNDZpb1bsODTSSEvTPvDfc5e4ZUEI9dEny_Wd737OnX8H8C7R0tggKngmpOGR9mOeZ1HIrY0LiknatNnz6SwZX0YnV_GV--DWuLLKrU9sHXWxMPSN_AiBRpRQEUf8afmTU9coyq66Fhq3YY-Y0-MB7H0-nn093-URMP5Jl8sMZHLUBPQQk5NnxtgV86wXjf72yTeCUr9g8kYEGj2EBw46smGn60dwy9b7cKdrJvlrH-5OXZr8MTQnw1NW1fNK43ldsXneMMR5LP9hryunctYVcqAUu94sNw3H5dSWUXP6j61wVaPjasnE12xRssloxqjWo-UBZWh1lhV4gV91rexxwidwOTq--DLmrrsCN4kQa661sNIX1o-CovS1MH4YWtywxGQmRNgWZWmoZYmQIQ7yvLRFGcvUhLkxYZBnaRkewKDGlT0DVkYRbnRJYAwBQSJ1KOLCIJKw9PBWSg8-bHdZLTsSDdVePmSiOpUoVIkilajMg7ekB0XkFDVVv3zPN02jJt_O1ZDQYYoATHjw3gmVC9SIyd1jAlwP8Vn1JA97knh6TH94q27lTm-j_tjaP4fxFib9hH4evNkN08RUsFbbxaadgoiIMPZ78LQznt1fpwbPREPrQdozq50AUX73R-pq3lJ_E1-cH6XP_7_q13BvfDE9U2eT2ekLuC9ae0eHKA5hsF5t7EvEUWv9yh2W3zX6Gww |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgiIkXBOMrMMAgJCQkL9-Jw1s1qNaNVhMwaW9W7Ng0UptWTfPAf8-d41YN4gn10RfL9d35ftadf0fIh0xypcOkYkXEFUtkkLKySGKmdVphTJLKZs-ns-ziJrm8TW8PWn3Zon0l67NmsTxr6rmtrVwvlb-rE_Ovp-fImhUkub-ujH-X3EtjMLLdRd0lECDwcZfEDHnmtyG-wGR4JEPQShmShWKf3cC-ODqISH-fyweBaVg0eRCFxo_IQwcf6ahf5mNyRzcn5H7fUPL3CTmeulT5E9Jejq5o3cxrCT67ofOypYD1aLnUi9qpnfbFHCBFF926axksp9EUG9R_tsJ1A4eXJRTf0pWhk_GMYr2H5QKlYHmaVnCJ3_Tt7GHCp-Rm_PXn-QVzHRaYyqJoy6SMNA8iHSRhZQIZqSCONexdpgoVA3RLijyW3ABsSMOyNLoyKc9VXCoVh2WRm_gZOWpgZS8INUkCe24QkAEoyLiMo7RSgCY0Pr7l3COfdrss1j2RhrAXEJ6JXjsCtCNQO6LwyHvUg0CCigYrYH6VXduKyY_vYoQIMQcQFnnkoxMyK9CIKt2DAlgPcloNJE8HkuBBaji8U7dwHtwKALZJhkVD6T-H4SbGgwx_Hnm3H8aJsWit0avOToFkRBD_PfK8N579X98Zn0fygVntBZD2ezgC3mDpv531v_zvL9-S4-svY_FtMrt6RR5E1inguIxOydF20-nXgLK28o31pz-UoSQr |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=JAK+inhibitor+has+the+amelioration+effect+in+lupus-prone+mice%3A+the+involvement+of+IFN+signature+gene+downregulation&rft.jtitle=BMC+immunology&rft.au=Ikeda%2C+Keigo&rft.au=Hayakawa%2C+Kunihiro&rft.au=Fujishiro%2C+Maki&rft.au=Kawasaki%2C+Mikiko&rft.date=2017-08-22&rft.issn=1471-2172&rft.eissn=1471-2172&rft.volume=18&rft.issue=1&rft_id=info:doi/10.1186%2Fs12865-017-0225-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12865_017_0225_9 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2172&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2172&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2172&client=summon |